M&A exercise goes past huge pharma acquisitions with Supernus Prescribed drugs and Indivior Prescribed drugs reaching a inventory deal that the businesses name a merger of equals. The mixed firm’s portfolio may have 11 commercialized merchandise in habit, attention-deficit hyperactivity dysfunction, despair, and Parkinson’s illness.
The submit Supernus and Indivior to Merge, Forming a New CNS-Targeted Pharma Firm appeared first on MedCity Information.
